Sarhan H, Grimaldi B, Hen R, Fillion G
Unité de Pharmacologie Neuro-Immuno-Endocrinienne, Institut Pasteur, Paris, France.
Naunyn Schmiedebergs Arch Pharmacol. 2000 Jan;361(1):12-8. doi: 10.1007/s002109900163.
In previous paper based on classical pharmacological tools, we identified a Gi protein-coupled presynaptic 5-hydroxytryptamine (5-HT) 1B receptor causing inhibition of dopamine (DA) release in rat striatal synaptosomes. It was the aim of the present study to further explore this receptor, using 5-HT moduline, a polyclonal antibody directed against 5-HT1B receptors and 5-HT1B receptor knock-out mice. Preincubation of rat striatal synaptosomes with 5-HT moduline (0.1, 1, or 10 microM) significantly reduced the inhibitory effect of CP93,129, a selective rat 5-HT1B receptor agonist, on K+-evoked overflow of [3H]DA in a non-competitive manner: 5-HT moduline did not modify the IC50 of CP93,129, but concentration-dependently reduced the maximal inhibitory effect. Preincubation of rat striatal synaptosomes with a specific polyclonal 5-HT1B receptor antibody also resulted in a significant attenuation of the inhibitory effect of CP93,129 on K+-evoked overflow of [3H]DA. In female 129/Sv wild-type mice, CP93,129 and 5-carboxyamidotryptamine maleate (5-CT), a non-selective 5-HT1B receptor agonist, inhibited the K+-evoked [3H]DA overflow in a concentration-dependent manner. Sumatriptan, a selective rat 5-HT1D receptor agonist, did not modify the overflow of [3H]DA. SB224289, a selective 5-HT1B receptor antagonist, abolished the inhibitory effects of CP93,129 and 5-CT. The inhibitory effects of CP93,129 and 5-CT were absent in synaptosomes from 5-HT1B receptor knockout mice. No compensatory inhibition effect in mutant mice was observed using sumatriptan. In conclusion, the results show that a non-competitive antagonist of the 5-HT1B receptor concentration-dependently decreases the maximal inhibitory effect of a 5-HT1B receptor agonist on the synaptosomal K+-evoked release of [3H]DA in striatum. Moreover, a specific antibody raised against the receptor and particularly directed against a region of the receptor protein involved in signal transduction, namely the coupling with the G-protein, also antagonizes the inhibitory effect of the stimulation of 5-HT1B receptor on the release of [3H]DA. Ultimately the disruption of 5-HT1B receptor gene in 5-HT1B knock-out mice leads to a total suppression of the effect of 5-HT1B receptor agonists on [3H]DA release. These observations further support our previous observations using selective agonists/antagonists, indicating that 5-HT1B receptors control the release of neuronal DA as presynaptic heteroreceptors.
在之前基于经典药理学工具的论文中,我们鉴定出一种Gi蛋白偶联的突触前5-羟色胺(5-HT)1B受体,其可抑制大鼠纹状体突触体中多巴胺(DA)的释放。本研究的目的是使用5-HT调节素、一种针对5-HT1B受体的多克隆抗体和5-HT1B受体基因敲除小鼠,进一步探究该受体。用5-HT调节素(0.1、1或10微摩尔)预孵育大鼠纹状体突触体,以非竞争性方式显著降低了选择性大鼠5-HT1B受体激动剂CP93,129对钾离子诱发的[3H]DA溢出的抑制作用:5-HT调节素未改变CP93,129的IC50,但浓度依赖性地降低了最大抑制作用。用特异性多克隆5-HT1B受体抗体预孵育大鼠纹状体突触体,也导致CP93,129对钾离子诱发的[3H]DA溢出的抑制作用显著减弱。在雌性129/Sv野生型小鼠中,CP93,129和5-羧酰胺色胺马来酸盐(5-CT,一种非选择性5-HT1B受体激动剂)以浓度依赖性方式抑制钾离子诱发的[3H]DA溢出。选择性大鼠5-HT1D受体激动剂舒马曲坦未改变[3H]DA的溢出。选择性5-HT1B受体拮抗剂SB224289消除了CP93,129和5-CT的抑制作用。5-HT1B受体基因敲除小鼠的突触体中未观察到CP93,129和5-CT的抑制作用。使用舒马曲坦未在突变小鼠中观察到代偿性抑制作用。总之,结果表明,5-HT1B受体的非竞争性拮抗剂浓度依赖性地降低了5-HT1B受体激动剂对纹状体突触体中钾离子诱发的[3H]DA释放的最大抑制作用。此外,针对该受体特别是针对受体蛋白中参与信号转导(即与G蛋白偶联)区域产生的特异性抗体,也拮抗了5-HT1B受体刺激对[3H]DA释放的抑制作用。最终,5-HT1B基因敲除小鼠中5-HT1B受体基因的破坏导致5-HT1B受体激动剂对[3H]DA释放的作用完全被抑制。这些观察结果进一步支持了我们之前使用选择性激动剂/拮抗剂的观察结果,表明5-HT1B受体作为突触前异受体控制神经元DA的释放。